Drugs / B6
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00054938 | Mar 2003 → Dec 2005 | systemic lupus erythematosus | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00202280 | Sep 2004 → Sep 2006 | psychotic disorder | Melbourne Health | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05619328 | Sep 2022 → Nov 2023 | sensory peripheral neuropathy | Procter and Gamble | Completed | No outcome recorded |
| Phase 3 | NCT00170404 | Jun 2000 → Oct 2005 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00217178 | Jan 2000 → Oct 2005 | atherosclerosis | Hamilton Health Sciences Corporation | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06446830 | May 2024 → Nov 2025 overdue | — | Ain Shams University | Recruiting | No outcome recorded |
| — | NCT00018460 | Apr 1999 → Mar 2002 | cardiovascular disorder | US Department of Veterans Affairs | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03887169 Background | Sep 2019 → Jun 2020 | inborn mitochondrial metabolism disorder, pulmonary alveolar proteinosis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00693589 Comparator | Jan 2005 → Feb 2007 | cardiovascular disorder | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00202280 ↗ |
| Known as | Vitamin B6 | “Effect of Homocysteine-lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Endothelium-dependent Vasodilatation of Forearm Resistance Vessels in Patients With...” NCT00693589 ↗ |
| Modality | Other / unclassified | “an adjunctive B-vitamin supplement” PMID 30771856 ↗ Jan 2019 |
| Route | Oral | “Vitamin supplementation with folic acid 1mg/d, vitamin B12 0.4mg/d and B6 10mg/d po for 6 weeks” NCT00693589 ↗ |